In detail, KRAS mutations led to the downregulation of HLA class I on the cell surface and the overexpression of PD-L1 and CD47 with the consequent prevention of innate and adaptative anti-cancer responses [79,80,81]. The gene discussed is KRAS; the disease is cancer.